IL-8 in endothelial cells 8 and also to stimulate endothelial cell proliferation and migration in vitro and angiogenesis in vivo. 23 The aim of this study was to investigate whether IL-33, when released as an alarmin, differs from IL-1 in activation of vascular endothelial cells. We show that IL-33 drives a global inflammatory response in cultured human umbilical vein endothelial cells (HUVEC) highly similar to that seen in response to IL-1β, but whereas IL-1β activates both quiescent and nonquiescent cells, IL-33 is a selective activator of the latter. This responsiveness correlated to lower levels of IL-33R and lower activation levels of downstream mediators nuclear factor-κB (NF-κB), p38, and JNK in quiescent cells and translated to a striking difference between quiescent and nonquiescent cells at the level of target protein expression.
Materials and Methods

Cell Culture
Umbilical cords were obtained from the Department of Gynaecology and Obstetrics, Oslo University Hospital, with the mothers' written permission, and in accordance with an approved study protocol (Regional Committee for Medical Research Ethics, Health Region South, Norway, Approval S-05152). HUVEC were isolated as described 24 and cultured as described in Materials and Methods in the online-only Data Supplement.
Cellular ELISA
HUVEC were stimulated with IL-1β or IL-33 for 6 or 16 hours before fixation in 0.5% periodate-lysine-paraformaldehyde (10 min). Fixed and dried monolayers were incubated with primary antibodies ( Table I in the online-only Data Supplement) followed by peroxidaseconjugated goat antimouse IgG (Sigma, A3673, 1/3000) and diaminobenzidine substrate, and read at 492 nm. Subsequent staining with crystal violet enabled compensation for variations in cell numbers. Neutralizing antibodies against IL-1R1 (IL-1R-specific goat IgG, AF269, R&D systems) or IL-33R (IL-33R-specific goat IgG, AF523, R&D systems) or kinase inhibitors as specified were added 1 hour before cytokine stimulation.
Western Blot
Western blots were performed with antibodies specified in Table I in the online-only Data Supplement, as described Materials and Methods in the online-only Data Supplement.
Tube Formation
Tube formation assays were performed as described in Materials and Methods in the online-only Data Supplement.
PCR and Microarray Analysis
Pooled HUVEC from 10 donors were seeded 1×10 4 cells/cm 2 and cultured for 4 days before stimulation for 4 hours with IL-1β 0.5 ng/mL or IL-33 50 ng/mL. Total RNA was isolated using the RNeasy Mini Kit (Qiagen), according to instructions of the manufacturer. Microarrays were performed using an Illumina Sentrix Human6 v2 Expression Beadchip, and the raw data were preprocessed by Illumina's BeadStudio software V2. The data have been deposited in NCBI's Gene Expression Omnibus 25 and are accessible through GEO Series accession GSE37624 (http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE37624). Quantile, normalized raw microarray intensities were used for further data analysis, 26 which is described in Materials and Methods in the online-only Data Supplement. Sequences of PCR primers are given in Table II in the online-only Data Supplement.
Cytokine Injection in Mouse Skin
All animal procedures were performed in accordance with national and institutional guidelines. C57BL/6J mice (n=3-4 per group, sexand age-matched, data shown are from female mice) were anaesthetized (isoflurane), shaved, and injected intradermally with carrier-free recombinant mouse IL-1β or IL-33. Four hours after injection, mice were sacrificed, and 5-mm punch biopsies of injection sites harvested and fixed (formalin/paraffin).
Immunostainings and Microscopy
Immunostainings and microscopy were performed as described in the online-only Data Supplement Materials and Methods. The generation of affinity-purified IL-33Nter rabbit polyclonal antibody has been described elsewhere. 27 All other antibodies for immunostainings and working concentrations are specified in Table I in the online-only Data Supplement.
Flow Cytometry
Flow cytometry was performed with antibodies specified in Table I in the online-only Data Supplement, as described in Materials and Methods in the online-only Data Supplement.
Fluorescent Cell Barcoded Phosphoflow Cytometry
Pooled HUVEC from 10 donors were seeded 1.5×10 4 cells/cm 2 and cultured for 4 days before stimulation for 30 min with IL-1β or IL-33. Single-cell suspensions were obtained by incubation on ice for 20 min with 5mM EDTA and 0.5% trypsin. The cells were fixed for 10 minutes at 37°C (BD Phosflow Fix Buffer I; BD Biosciences) and washed in PBS before 2-dimensional fluorescent cell barcoding was performed, as described 28 using Pacific Blue and Alexa488 (Molecular Probes, Invitrogen). The cells were washed (PBS, 1% FBS), combined, permeablilized (-20°C cold BD Phosflow Perm Buffer III; BD Biosciences), and stored at -80°C. The cells were washed again and stained with the indicated antibodies ( Table I in the online-only Data Supplement), before analysis with a BD FACSCanto II (4-2-2) cytometer equipped with 405-, 488-, and 633-nm lasers. Compensation was performed for the antibody fluorochromes using a compensation particle set (BD Biosciences), whereas separately stained cells were used for the barcoding fluorochromes. Data were analyzed using Cytobank software (https://www.cytobank.org/cytobank/). Signals were calculated as the inverse hyperbolic sine (arcsinh) of the median fluorescence intensity of stimulated versus unstimulated cell populations.
siRNA Knockdown and Adenoviral Transduction
Silencer predesigned siRNA targeting IL-33 (siRNA ID# 131654, 131655, 35368, 35460, 35551) or negative controls (silencer negative control siRNAs #1, 2, 3) were obtained from Ambion and used according to manufacturer's instructions. Adenoviral transduction was performed as outlined in Materials and Methods in the onlineonly Data Supplement.
Statistics
All experiments were conducted at least 3 times with HUVEC from different donors, unless otherwise indicated. P-values were calculated in Graph Pad Prism 5 using 1-way ANOVA and Bonferroni testing, are 2-sided and considered significant when <0.05.
Results
IL-33 Activates Endothelial Cells in a Manner Highly Similar to IL-1β and Acts via IL-33R
We first compared the effects of IL-33 and IL-1β on the expression of endothelial adhesion molecules in vitro, finding that both cytokines induced E-selectin ( Figure 1A ) and intercellular adhesion molecule-1 (ICAM-1) ( Figure IA in the online-only Data Supplement) in a concentrationdependent manner with similar peaks in expression levels, but with almost 2 orders of magnitude higher sensitivity for IL-1β compared with IL-33 (EC 50 0.1 and 5 ng/mL, and E max 1 and 100 ng/mL, respectively). Furthermore, a polyclonal antibody to IL-33R blocked the IL-33-induced E-selectin expression, but had no effect on E-selectin induced by IL-1β ( Figure 1B ). Conversely, neutralizing anti-IL-1R1 abolished IL-1β-induced E-selectin expression, but did not influence the IL-33-mediated induction ( Figure 1B ). We also assessed the time course of E-selectin and extracellular signal-regulated kinase-1 induction in response to IL-33, observing kinetics identical to the response induced by IL-1β ( Figure IB and IC in the onlineonly Data Supplement).
Next, we analyzed the involvement of putative downstream mediators. Phospho-Western blot showed that IL-1β and IL-33 induced phosphorylation of IκBα, p38, JNK, and extracellular signal-regulated kinase-1/2 with similar kinetics ( Figure 1C ). Furthermore, both IL-1β-and IL-33-induced expression of E-selectin was abolished by inhibitors of NF-κB (pyrrolidine dithiocarbamate) and reduced by inhibitors of p38 (SB202190) and JNK (SP600125; Figure 1D ). However, inhibition of mitogen-activated protein kinase kinase by means of compounds PD98059 did not significantly affect expression of E-selectin upon treatment with either cytokine ( Figure 1D ). Similar results were obtained by evaluating the effect of these inhibitors on ICAM-1 upregulation (data not shown).
IL-33 and IL-1β Drives Tube Formation in a Similar Fashion
It has previously been demonstrated that IL-33 is able to drive tube formation in cultured endothelial cells, 23 and we therefore compared the effects of IL-33 and IL-1β on HUVEC in a simple 2-dimensional matrigel system, observing in accordance with previous findings that IL-33 stimulated this behavior and that the same effect could be observed after IL-1β stimulation, with EC 50 30 and 0.1 ng/mL, respectively ( Figure 1E ).
The Transcriptional Responses of HUVEC to IL-33 and IL-1β Are Highly Similar
To further confirm that the effect of IL-33 on HUVEC closely resembles that of IL-1β, we compared the genome-wide transcription profile of confluent endothelial cell cultures after 4 hours exposure to IL-33 or IL-1β. As suspected, analysis of these data revealed a striking similarity in the transcriptional response to the 2 cytokines. Figure 2A shows genes significantly induced (false discovery rate<0.05) by IL-1β (green cross, 476 genes) and IL-33 (red circle, 317 genes; please refer to the online-only Data Supplement information for more detail). Among these genes ≈305 are overlapping between IL-1β and IL-33. Hypergeometric testing of genes that are common for both conditions gives a P-value <3e-16, indicating that the transcriptional response induced in HUVEC by the 2 cytokines is very similar. Nevertheless, a larger number of genes are induced by IL-1β than by IL-33, when considered to the same level of statistical significance. Heatmaps of some of the most strongly regulated genes in the categories of immune response, angiogenesis, proliferation, and programmed cell death (classified using DAVID) 29 are shown in Figure 2B . Results were confirmed by real-time PCR of selected genes at different time points after stimulation with IL-1β or IL-33 ( Figure II in the online-only Data
The Proinflammatory In Vivo Response to IL-33 Is Weak to Moderate in Skin Vessels
Given the strikingly similar response of cultured endothelial cells to IL-1β or IL-33, we decided to assess the proinflammatory effect of IL-33 in vivo by intradermal injection of recombinant murine IL-1β or IL-33 in C57BL/6J mice. Immunohistochemical estimation of infiltrating Ly6Gpositive granulocytes revealed peak infiltration between 4 and 8 hours in response to both cytokines, but whereas IL-1β induced high numbers already at 20 ng per injection site, we were surprised to find only a weak-to-moderate infiltration in response to single injections of IL-33 in doses up to 3 µg (panels in Figure 3A show sites injected with 50 and 500 ng, respectively). To more directly address the effect of cytokines on the vascular endothelium, we enumerated the fraction of vessels that expressed the endothelial-specific adhesion molecule E-selectin 4 hours after injection of IL-1β or IL-33, observing a vascular induction of E-selectin in 51±11% of the vessels in response to IL-1β, and significantly fewer positive vessels after injection of IL-33 (26±12%; corresponding numbers for vehicle-injected skin were 18±8%, Figure 3A ). To assess whether the in vivo difference between IL-1 and IL-33 might affect the recruitment of other leukocyte populations, we also immunostained samples to detect F4/80positive macrophages ( Figure IIIA in the online-only Data Supplement) and CD3-positive T cells (data not shown), detecting no increase in either population compared with vehicle-injected injection sites. An estimate of total leukocyte numbers based on immunostainings for CD45 showed a trend compliant with the pattern seen for granulocytes ( Figure IIIB in the online-only Data Supplement), but did not reach significance.
IL-33 Preferentially Activates Nonquiescent HUVEC
The surprisingly weak effect of IL-33 on endothelial cell activation in vivo, compared with that seen in vitro, made us speculate whether endothelial cell responsiveness could be related to properties of cultured cells, such as their level of confluence or proliferation status. To this end, we compared the IL-33response in HUVEC cultures containing areas of low and high cellular density, using immunostaining for E-selectin as readout. We observed that IL-1β induced E-selectin expression in virtually all cells, irrespective of density and status of quiescence, but that IL-33 predominantly activated nonquiescent endothelial cells expressing undetectable or low levels of the quiescence-associated proteins, such as nuclear IL-33, 27,30 VE-cadherin, 31 and CD31 27 ( Figure 3B ). The selectivity of IL-33 for nonquiescent cells was also observed when assessing the expression of ICAM-1 and IL-8 ( Figure 3C) and was a particular feature of IL-33, because other endothelial cell activators such as tumor necrosis factor (TNF)-α or lipopolysaccharide (readout: E-selectin), interferon-γ (readout: human leukocyte antigen-DR), and IL-4 (readout: eotaxin-3), like IL-1β, activated both quiescent and nonquiescent cells in the same manner ( Figure 3C) . To confirm the observed differences in E-selectin response, HUVEC seeded at different densities were stimulated with increasing doses of IL-1β or IL-33 for 6 hours, and E-selectin levels were measured by cellular ELISA, followed by crystal violet staining to assess cell density ( Figure IVA in the online-only Data Supplement) or FACS ( Figure IVB in the online-only Data Supplement). As expected, the level of confluence strongly affected the responsiveness to IL-33 stimulation, but had little influence on the response to IL-1β.
Cells From Confluent Cultures That Express E-Selectin in Response to IL-33 Are Nonquiescent
To further characterize the IL-33-responsive cells, we next sorted E-sel hi and E-sel lo cells activated by IL-33 and analyzed cell lysates by Western blot with antibodies to hyperphosphorylated retinoblastoma protein (ppRb, a G1/S transition marker), cyclin-D1 (a marker of actively proliferating cells), p27 (a marker of cellular quiescence), and nuclear IL-33. We observed that the E-sel hi population expressed higher levels of ppRb and cyclin-D1, and lower levels of p27 and nuclear IL-33 than the E-sel lo population, compatible with the hypothesis that the responsiveness to IL-33 mainly resided in nonquiescent, proliferating cells ( Figure 3D ).
IL-33 Induces Intracellular Signaling Selectively in Nonquiescent Endothelial Cells
To assess intracellular signaling induced by IL-33 and IL-1β in quiescent and nonquiescent endothelial cells in a more quantitative way, we performed multiparameter phosphoflow cytometry using ppRb as a marker for nonquiescence. 10 Fluorescent cell barcoding was used to allow cells from different treatment groups to be stained and analyzed together, thus achieving identical experimental conditions in all groups. We analyzed the phosphorylation state of NF-κB, p38, and stress-activated protein kinase/ JNK in quiescent versus nonquiescent cells, upon stimulation with 4 different concentrations of IL-1β or IL-33 ( Figure 4A ). In agreement with our observations described above, IL-1β induced phosphorylation of these proteins to a similar level in both quiescent and nonquiescent cells, whereas IL-33 preferentially stimulated nonquiescent cells (Figure 4 ).
Expression of IL-33R Is Higher in Subconfluent Cells
We next assessed whether the restricted responsiveness to IL-33 might be related to the expression levels of IL-33R. FACS analysis of single-cell suspensions ( Figure 5A) and Western blot analysis of cell lysates ( Figure 5B ) from subconfluent and confluent cell cultures revealed a substantially stronger signal for both soluble and membrane-bound IL-33R in subconfluent populations, well in line with the observed responsiveness to IL-33 as well as previous observations that IL-33R is increased in proliferating cells. 8 
Expression of IL-33R Correlates With IL-33 Responsiveness on a Single Cell Level
To correlate the expression of IL-33R and the responsiveness to IL-33 on a single-cell level, we analyzed the contents of IL-33R in lysates from the FACS-separated E-sel lo and E-sel hi populations described in Figure 3D , confirming higher levels of IL-33R in the IL-33-responsive or E-sel hi population ( Figure 5C ).
Modification of Nuclear IL-33 Does Not Alter the Sensitivity to IL-33
Given that nuclear IL-33 is thought to possess transcriptional repressor properties 32 and dock to nucleosomal proteins, 33 as well as a recent report that IL-33 might dampen NF-κBinduced proinflammatory signaling, 34 we found it highly interesting that expression of nuclear IL-33 and responsiveness to exogenous IL-33 were negatively correlated. We therefore considered that if nuclear IL-33 were involved in the control of vascular integrity and quiescence, 27 it might affect responsiveness to exogenous IL-33. However, knockdown of IL-33 by means of siRNA failed to enhance the E-selectin response to recombinant IL-33 in contact-inhibited cells ( Figure 5D ), and overexpression of IL-33 in subconfluent cells by adenoviral transduction did not prevent induction of E-selectin by IL-33 exposure ( Figure 5E ). This suggests that nuclear IL-33 expression alone is insufficient to guide the cell response and that other factors may be involved.
Discussion
This study shows that quiescent endothelial cells are surprisingly resistant to proinflammatory activation by the alarmin IL-33, in contrast to the response induced by other proinflammatory cytokines, such as IL-1β, IL-4, interferon-γ, and TNF-α. Instead, IL-33 drives a response that translates into a selective induction of adhesion molecules and chemokines in nonquiescent, proliferating endothelial cells. Indeed, this response closely resembles that driven by IL-1β, not only on the level of target protein expression, but also with regards to phosphorylation of signaling molecules, induction of tube formation, and transcriptional profile. Although substantial redundancy exists between endothelial responses to TNF-α and IL-1β, 22, 35 comparison of our microarray data to previous studies revealed that IL-33 upregulated genes reported to be induced by IL-1β, but not TNF-α, including SERPINB2, CXCL1, CD47 ( Figure 2B ), and ZFP36 (data not shown). 22 Furthermore, in the same study, TNFα induced a longer-acting upregulation of vascular cell adhesion molecule-1 (VCAM-1)-1 mRNA than IL-1β, 22 whereas kinetics for VCAM-1 mRNA induction by IL-33 and IL-1β in our hands were identical ( Figure 2C ). The resistance of quiescent cells to IL-33 stimulation was convincingly demonstrated by our immunostainings to E-selectin, ICAM-1, and IL-8, and was further reflected in observing a strong reduction in kinase activation in response to IL-33 in quiescent (ppRb lo ) compared with nonquiescent (ppRb hi ) endothelial cells. In our hands, the IL-33-induced intracellular signaling, resulting in endothelial E-selectin expression, appeared to involve the mediators originally reported to be phosphorylated in response to IL-33 in polarized Th2 cells and mast cells. 1 Previous studies have reported phosphorylation of extracellular signal-regulated kinase 1/2 in endothelial cells in response to IL-33, but no evidence for activation of JNK or p38 mitogen-associated protein kinases. 8 Here, we have mapped and compared the phosphorylation of signaling molecules induced by IL-33 and IL-1β, first on a population basis by traditional Western blotting, showing that the cytokines induce a similar signaling pattern in HUVEC, and second on the individual cell level by multiparameter flow cytometry, using fluorescent barcoding to minimize experimental variability between samples. 28 To our knowledge, analysis of endothelial cells by multiparameter phosphoflow cytometry has not been previously reported, and represents a novel and valuable approach for distinguishing between responses of endothelial subpopulations. Using this method to compare cytokine-induced phosphorylation, we showed that phosphorylation of NF-κB p65 (pS529), p38 (T180, Y182), and JNK (pT183, pY185) is higher in proliferating, nonquiescent (ppRb hi ) compared with quiescent (ppRb lo ) HUVEC from superconfluent cultures, when stimulated with IL-33, but not IL-1β. Taken together, our finding that membrane-bound IL-33R is preferentially expressed in subconfluent HUVEC cultures compared with confluent cultures can at least partly explain the lack of responsiveness to IL-33 in contact-inhibited cells, although additional mechanisms downstream of receptor engagement may serve to further corroborate this effect.
It is interesting to note that the lack of IL-33 reponsiveness in vitro appears to reflect how IL-33 acts on resting vessels in vivo because intradermal injection of IL-33 induced a surprisingly weak inflammatory response in healthy mouse skin compared with that initiated by injection of IL-1β. This is also in agreement with previous studies reporting that IL-33-induced swelling and cellular recruitment appeared as late as 7 to 10 days after repeated intradermal injections of IL-33. 36, 37 In further support of our observation, a recent study of scleroderma patients revealed that quiescent, IL-33-positive vessels of healthy skin showed undetectable vascular expression of IL-33R, whereas early activated vessels in scleroderma lesions displayed the inverse phenotype. 38 Thus, it would appear that the action of IL-33 requires previous endothelial cell activation and, in practical terms, our findings describe a mechanism by which quiescent endothelial cells in established vessels may remain nonresponsive to a stimulus that triggers a powerful inflammatory activation in cells that have been released from contact inhibition.
Because IL-33R was first reported as an early-response gene to mitogens, 39 and is upregulated in proliferating endothelial cells, 8 it is tempting also to view our results in an angiogenic context. When endothelial cells of preexisting vessels are engaged in angiogenesis, there is formation of a leading, migrating cell referred to as a tip cell, behind which proliferating endothelial cells referred to as stalk cells extend. 40 In the view of our findings, the dividing stalk cells are likely to express IL-33R, and therefore be receptive to IL-33 released by necrotic or activated cells in adjacent tissues. Indeed, IL-33 was recently found to stimulate angiogenic behavior in endothelial cells in vitro and in vivo. 23 Although our data confirm the stimulation of tube formation in HUVEC on a 2-dimensional matrigel system in response to both IL-33 and IL-1β, one should keep in mind that the well-established role of IL-1β, and to a lesser degree IL-1α, in promoting tumor angiogenesis 41 seems to rely mainly upon stimulation of tissue-resident cells like macrophages to produce vascular endothelial growth factor and other factors driving angiogenesis, rather than a predominant effect on the endothelial cells themselves. , 41, 4243 The same could be true for the in vivo angiogenesis observed in matrigel plugs with IL-33, 23 as the endothelial response might be partly or entirely secondary to macrophage activation rather than a specific endothelial response to the tested cytokines. 42 It remains an interesting observation that nonresponding cells have a prominent expression of IL-33 in their nuclei, in particular when considering the recent observation that IL-33 might dampen NF-κB-induced proinflammatory signaling in fibroblasts, 34 leading us to speculate that nuclear IL-33 could also serve as a molecular brake in endothelial cells to control undue activation of quiescent vasculature. Although we have not excluded this possibility for proinflammatory stimuli, in general, it appears that expression of nuclear IL-33 does not specifically regulate the nonresponsiveness to exogenous IL-33 in quiescent endothelial cells. Rather, it appears that expression of nuclear IL-33 and lack of expression of IL-33R are 2 concurrent, but not causally related features of quiescent, contact-inhibited cells.
In conclusion, we describe a novel level of regulation for a member of the proinflammatory IL-1 family of cytokines in endothelial cells, according to which the activation state of the cell controls the expression level of the receptor and determines the ability to respond to free ligand.
